ONWARD Medical: New Shares Listed on Euronext Following Private Placement Closure
ONWARD Medical announced on Monday the closure of its private placement with institutional investors. The new shares from this operation are now admitted for trading on the regulated markets of Euronext.
Completion of Private Placement and Listing on Euronext
The neurotechnology company ONWARD Medical has completed its previously announced private placement. Starting Monday, the new shares from this operation are admitted for trading and exchange on Euronext Brussels, Euronext Amsterdam, and Euronext Paris.
ONWARD Medical: A Leader in Neurotechnology
ONWARD Medical positions itself as a leading company in neurotechnology, pioneering the development of therapies designed to restore movement, function, and independence in individuals suffering from spinal cord injuries and other movement disorders. The company has developed its proprietary ARC Therapy, based on decades of scientific research and clinical studies. Its ARC-EX® system is authorized for commercial sale in the United States and Europe. ONWARD Medical is also developing an investigational implantable system called ARC-IM®, designed to address several unmet needs including blood pressure instability post-spinal injury, and can be integrated with a brain-computer interface and artificial intelligence to restore thought-controlled movement. The company is headquartered in the Netherlands, with a science and engineering center in Switzerland and an office in Boston, Massachusetts, USA.
